NewAmsterdam Pharma Hits Day High with 8.05% Surge, Strong Intraday Performance
NewAmsterdam Pharma Co. NV has seen notable stock performance, gaining 8.05% on October 30, 2025, and achieving a 36.15% increase over the past month. The company reported significant growth in net sales and maintains 100% institutional holdings, despite facing challenges with negative EBITDA and pre-tax losses.
NewAmsterdam Pharma Co. NV has experienced a significant uptick in its stock performance, gaining 8.05% on October 30, 2025. The stock reached an intraday high of USD 39.03, reflecting a strong day of trading for the small-cap pharmaceutical and biotechnology company. Over the past month, NewAmsterdam Pharma has shown impressive growth, with a 36.15% increase, significantly outperforming the S&P 500, which rose only 3.44% during the same period. The company's year-to-date performance stands at 50.66%, while its one-year return is an impressive 115.11%, compared to the S&P 500's 18.13%.
Despite the positive momentum, NewAmsterdam Pharma faces challenges, including a negative EBITDA and a pre-tax profit of USD -19.95 million, although this figure has improved by 58.72% compared to previous quarters. The company has also reported a remarkable 740.06% growth in net sales for the quarter, amounting to USD 19.14 million.
With institutional holdings at 100%, NewAmsterdam Pharma continues to demonstrate strong market performance, making it a noteworthy player in the pharmaceuticals and biotechnology sector.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
